William Guyer - 01 Dec 2025 Form 4 Insider Report for CORCEPT THERAPEUTICS INC (CORT)

Reporting relationship: Chief Development Officer
Issuer ticker: CORT
Reported as of: 01 Dec 2025
Net transaction value: -$1,150,655
SEC form: 4
Accepted by SEC: 03 Dec 2025, 21:19:27 UTC
Prior SEC filing: 26 Nov 2025
Next SEC filing: 08 Jan 2026
Source filing: View source filing
Reporting owner signature: /s/ Joseph Douglas Lyon, as attorney-in-fact for William Guyer.

Key filing fact

William Guyer filed Form 4 for CORCEPT THERAPEUTICS INC (CORT) on 03 Dec 2025.

Key facts

This page summarizes William Guyer's Form 4 filing for CORCEPT THERAPEUTICS INC (CORT).
8 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 03 Dec 2025, 21:19.

Change

Previous filing in this sequence was filed on 26 Nov 2025.
Current net transaction value: -$1,150,655.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001879013 Primary reporting owner

Guyer William

Relationship: Chief Development Officer
Address: C/O CORCEPT THERAPEUTICS INCORPORATED, 101 REDWOOD SHORES PARKWAY, REDWOOD CITY
Signature: /s/ Joseph Douglas Lyon, as attorney-in-fact for William Guyer.
Signature date: 03 Dec 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

CORT transaction

Common Stock

Award

Transaction value: $17,871
Shares: +224
Change %
Price: $79.78
Shares after: 224
Date: 01 Dec 2025
Ownership: Direct
Footnotes: F1, F2

CORT transaction

Common Stock

Award

Transaction value: $0
Shares: +224
Change %: +100%
Price: $0.000000
Shares after: 448
Date: 01 Dec 2025
Ownership: Direct
Footnotes: F3

CORT transaction

Common Stock

Gift

Transaction value: $0
Shares: -787
Change %: -100%
Price: $0.000000
Shares after: 0
Date: 02 Dec 2025
Ownership: The Lake Bainwood Living Trust
Footnotes: F4

CORT transaction

Common Stock

Other

Transaction value: $0
Shares: +787
Change %: +176%
Price: $0.000000
Shares after: 1,235
Date: 02 Dec 2025
Ownership: Direct
Footnotes: F5

CORT transaction

Common Stock

Options Exercise

Transaction value: $433,000
Shares: +20,000
Change %: +1619%
Price: $21.65
Shares after: 21,235
Date: 02 Dec 2025
Ownership: Direct

CORT transaction

Common Stock

Sale

Transaction value: $1,549,766
Shares: -19,360
Change %: -91%
Price: $80.05
Shares after: 1,875
Date: 02 Dec 2025
Ownership: Direct
Footnotes: F6, F7

CORT transaction

Common Stock

Sale

Transaction value: $51,760
Shares: -640
Change %: -34%
Price: $80.88
Shares after: 1,235
Date: 02 Dec 2025
Ownership: Direct
Footnotes: F6

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CORT transaction Derivative

Stock option (right to buy)

Options Exercise

Transaction value: $0
Shares: -20,000
Change %: -6.9%
Price: $0.000000
Shares after: 270,000
Date: 02 Dec 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 20,000
Exercise price: $21.65
Footnotes: F8

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 8 footnotes

Footnote F1

The Reporting Person purchased shares ("Purchase Plan Shares") of the Issuer's common stock pursuant to a purchase plan ("Purchase Plan") established under the Corcept Therapeutics Incorporated 2024 Incentive Award Plan on December 1, 2025.

Footnote F2

In accordance with the Purchase Plan, the price was established based on the closing price on the day of the purchase.

Footnote F3

Shares underlie unvested restricted stock awards granted to the Reporting Person by the Issuer under the Purchase Plan. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person remains the beneficial owner of the Purchase Plan Shares through such one-year anniversary.

Footnote F4

Represents the shares held by The Lake Bainwood Living Trust of which the Reporting Person is a co-trustee.

Footnote F5

Transfer of shares without consideration to the Reporting Person.

Footnote F6

This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on November 27, 2024 in effect at the time of this transaction.

Footnote F7

Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $79.78 to $80.68 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.

Footnote F8

Fully exercisable.

SEC remarks

The power of attorney under which this form was signed is on file with the Commission.